Study of a new drug combo for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two investigational drugs for people with advanced or metastatic esophageal squamous cell carcinoma. The goal is to see if the combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread to other parts of the body.
- You are willing to provide a sample of your tumor tissue (either from a past biopsy or a new one) for testing.
- You have at least one tumor that can be measured on scans.
- You are in generally good health, able to take care of yourself (ECOG score of 0 or 1), and expected to live at least 12 weeks.
- You have not had certain prior treatments (like topoisomerase I inhibitor antibody drugs) and are willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new form of chemotherapy (docetaxel albumin-bound), an immunotherapy (SG001), and standard chemotherapy (cisplatin) plus radiation for people with advanced esophageal cancer that cannot be surgically removed. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This study tests a new drug (SHR-9839) alone or combined with standard chemotherapy and another immunotherapy drug (adebrelimab) for advanced esophageal cancer. The goal is to see if this combination helps shrink tumors or slow cancer growth better than the standard treatment.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This study tests a new combination of drugs (adebelimab, apatinib, and chemotherapy or chemoradiation) for people with esophageal cancer that has gotten worse after prior immunotherapy. It aims to see if this combination can help when standard first-line treatment stops working.
This trial tests a combination of medicines to treat advanced esophageal squamous cell carcinoma (throat/esophagus cancer) that cannot be removed by surgery and has spread or come back. It is for people whose first treatment (chemotherapy or immunotherapy) did not work well or was not tolerated.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
Hear when a new Advanced or Metastatic Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.